Key result
Antiplatelet therapy is essential for the secondary prevention of cardiovascular disease by inhibiting platelet activation, aggregation, and subsequent arterial thrombus formation.
A review discussing the mechanism of action of antiplatelets and their place in therapy for secondary prevention of cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Supports established antiplatelet role in secondary prevention; extends mechanistic insights but leaves optimal regimens open for prospective trials.
Antiplatelets are widely used drugs that can prevent platelet activation and subsequent aggregation, inhibiting arterial thrombus formation that can contribute to the development of myocardial infarction and stroke. The use of antiplatelets for secondary prevention of cardiovascular disease is supported by a strong and compelling evidence base, with rigorous clinical trials supporting the use of varying combinations of antiplatelets for different indications. A sound understanding of how antiplatelets work is needed to promote their safe and effective use. This article briefly describes the process of platelet activation, aggregation and subsequent thrombus formation, and will discuss the mechanism of action of antiplatelets and their place in therapy.
No takes yet. Share an insight, caveat, or question.
Amie Bain (2018) conducted a review in Cardiovascular disease. Antiplatelets was evaluated. Antiplatelet therapy is essential for the secondary prevention of cardiovascular disease by inhibiting platelet activation, aggregation, and subsequent arterial thrombus formation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: